[The impact of glycosylated hemoglobin target value in treatment guidelines on glycemic control of type 2 diabetic in Chinese cities].
To investigate the influence of glycosylated hemoglobin Al c (HbA1c) standard value (2007 and 2010 Chinese Diabetes Prevention Guide) on glycemic control and treatment of type 2 diabetic patients in Chinese cities. A cross-sectional study was carried out in type 2 diabetes mellitus from outpatients in selected hospitals all over China in 2009 and 2012. Patients treated with oral antidiabetic drugs (OADs), insulin or OAD combined with insulin were enrolled. A questionnaire including general characters, therapy, complications and blood glucose was completed by trained surveyors. A total of 30 853 patients were enrolled in 2009, and 48 232 patients in 2012. The distribution of HbAlc < 6.5%, 6.5% - <7.0%, 7.0% - <8.0%, 8.0% - <9.0%, 9.0% - <10.0% and > or = 10.0% was 20.35%, 12.59%, 35.50%, 18.94%, 6.46% and 6.16% in 2012; 14. 81%, 27.72%,14.55%, 6.55% and 8.36% in 2009, respectively. The top three OAD were biguanides, sulfonylureas and thiazolidine. The most common treatment options for combined therapy are metformin combined with sulfonylurea in both 2009 and 2012. There is an increase in the proportion of patients with good and general blood glucose control in 2012. With the generalization of Chinese Diabetes Prevention Guide, a steady tendency is presented in blood gluense control.